drug

CT1812

1 story · latest Nov 5, 2026

Follow CT1812. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Cognition Therapeutics

Timeline

Cognition Therapeutics advances zervimesine toward Phase 3 in DLB, faces Nasdaq bid price notice

Nov 5Quarterly updateCognition Therapeutics

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.